I graduated from the University of Ioannina Medical School, Ioannina Greece in 2004, where I also completed my PhD in Medicine in 2014. I completed my Specialty training in Internal Medicine (CCT in General Internal Medicine) in the University Hospital of Ioannina, Ioannina, Greece in 2013.
Since 2005 I have been an active clinical researcher having participated as an Investigator in numerous clinical trials of all phases. I have designed a number of clinical studies in the areas of my expertise in Atherosclerosis prevention, Cardiovascular Pharmacology and Dyslipidaemias. This is an activity that I maintained throughout my PhD years, my specialty training and post-CCT to this date.
In parallel with my research activity I have been working clinically 1] as a Clinical Fellow (pre-CCT) in the Lipids and Cardiovascular risk management clinic of the University Hospital of Ioannina (2005-2013), and 2] as a Consultant Lipidologist in the Addenbrooke's Hospital Lipid clinic (2016-to date).
I was appointed in Addenbrooke's Hospital in 2014, first as a Senior Clinical Fellow (post-CCT) in the Clinical Pharmacology Unit. In there, I continued my clinical research activity together with obtaining my sub-specialty expertise in Hypertension.
In 2016 I was appointed as a Consultant in Acute Medicine and have been working in the Acute Medicine department leading the medical take. My post includes a secondment to the GlaxoSmithKline (GSK)'s Clinical Unit Cambridge (joint clinical and research post through secondment agreement between the CUH, GSK's Research and Development and myself).
I trained as a First in Human Phase 1 Clinical Trials Principal Investigator through the Diploma in Human Pharmacology postgraduate training. Subsequently, having passed the relevant exam I was awarded the Diploma in Human Pharmacology (DHP), by the Faculty of Pharmaceutical Medicine in 2018. DHP is the MHRA-accredited qualification for conducting First in Human Phase 1 Clinical Trials as a Principal Investigator. Through my work in the GSK's Early Phase Clinical Trials Unit in Cambridge I have been leading the design and conduct of Early Phase Clinical trials and Experimental Medicine studies and participate in Expert Panels for identifying new targets for drug development in Metabolic Medicine.
I maintain international interactions and academic collaborations with European Universities and academics.